NervGen Pharma (9UA) Stock Overview
A biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
9UA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
NervGen Pharma Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.90 |
| 52 Week High | US$5.00 |
| 52 Week Low | US$1.27 |
| Beta | 0.73 |
| 1 Month Change | 24.18% |
| 3 Month Change | 22.58% |
| 1 Year Change | -13.64% |
| 3 Year Change | 31.94% |
| 5 Year Change | n/a |
| Change since IPO | 31.03% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9UA | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -2.6% | -2.0% | -1.5% |
| 1Y | -13.6% | 40.8% | 4.0% |
Return vs Industry: 9UA underperformed the German Pharmaceuticals industry which returned 39.7% over the past year.
Return vs Market: 9UA underperformed the German Market which returned 4.2% over the past year.
Price Volatility
| 9UA volatility | |
|---|---|
| 9UA Average Weekly Movement | 14.7% |
| Pharmaceuticals Industry Average Movement | 4.9% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 12.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 9UA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 9UA's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 10 | Adam Rogers | nervgen.com |
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company’s lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer’s disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage.
NervGen Pharma Corp. Fundamentals Summary
| 9UA fundamental statistics | |
|---|---|
| Market cap | €202.61m |
| Earnings (TTM) | -€38.54m |
| Revenue (TTM) | n/a |
Is 9UA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9UA income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$61.96m |
| Earnings | -CA$61.96m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.58 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 9UA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/14 10:58 |
| End of Day Share Price | 2026/09/11 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
NervGen Pharma Corp. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Marc Goodman | Leerink Partners LLC |
| Elemer Piros | Lucid Capital Markets |